Related Experiment Videos

Antifungal properties of a novel 1,2,4-triazine derivative I 319

Insights

The sodium salt of 3-thiolo-5-phenyl-1,2,4-triazine (I 319) shows potent antifungal activity against pathogenic fungi. In vivo studies demonstrated significant survival benefits in a mouse model of candidiasis.

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Fungal infections pose a significant global health challenge, necessitating the development of novel antifungal agents.
  • Candida albicans is a common opportunistic pathogen responsible for various infections, from superficial to life-threatening systemic candidiasis.
  • The development of effective antifungal therapies with favorable safety profiles remains a critical area of research.

Purpose of the Study:

  • To evaluate the in vitro and in vivo antifungal efficacy of the sodium salt of 3-thiolo-5-phenyl-1,2,4-triazine (I 319).
  • To determine the minimal inhibitory concentration (MIC) of I 319 against a range of fungal strains.
  • To assess the therapeutic potential of I 319 in a murine model of subacute candidiasis.

Main Methods:

  • In vitro antifungal activity was assessed by determining the minimal inhibitory concentration (MIC) against 33 fungal strains.
  • In vivo efficacy was evaluated using a subacute candidiasis model in Balb/c mice infected with Candida albicans.
  • Antifungal activity in vivo was measured by changes in animal lifespan and quantification of fungal burden in key organs (kidneys, liver, spleen).

Main Results:

  • The minimal inhibitory concentration (MIC) of I 319 ranged from 3.1 to 25 microgram/ml against 33 pathogenic and saprophytic fungal strains.
  • A single intraperitoneal (i.p.) dose of I 319 (25 mg/kg) increased the survival time of infected mice by up to 200%.
  • Multiple doses of I 319 significantly reduced the number of Candida albicans cells in the kidneys, liver, and spleen of treated mice.

Conclusions:

  • The sodium salt of 3-thiolo-5-phenyl-1,2,4-triazine (I 319) exhibits significant in vitro and in vivo antifungal activity.
  • I 319 demonstrates therapeutic potential for treating Candida albicans infections, as evidenced by increased survival and reduced fungal burden in a murine model.
  • Further investigation into I 319 as a potential antifungal drug candidate is warranted.

Related Concept Videos